Peptides can be administered in several different ways, including injection, oral capsules, nasal sprays, sublingual products and topical formulations. In some cases, the same peptide may even be available or discussed in more than one form. This raises an important practical question: does the route of administration actually change how well a peptide is absorbed and whether it can produce an effect?
In many cases, yes. Injection generally provides more predictable systemic exposure because it bypasses the digestive tract, but that does not mean every peptide must be injected to have biological activity. Some peptides are unusually stable in gastrointestinal conditions, some have been specifically studied through nasal administration, and others may be used topically when local tissue rather than the bloodstream is the primary target.
BPC-157 demonstrates why the answer is not as simple as “injectable works, oral doesn’t.” Published experimental literature describes BPC-157 as unusually stable in gastric conditions and reports biological effects after oral administration in animal models. At the same time, good human pharmacokinetic research has not established how much orally administered BPC-157 reaches systemic circulation compared with subcutaneous administration. Injection therefore offers a more direct and predictable route to systemic exposure, but that is not the same thing as proving that injected BPC-157 produces better clinical results in humans.
What Does Peptide Bioavailability Actually Mean?
Bioavailability refers more specifically to the proportion of an administered substance that reaches systemic circulation in an available form. Intravenous administration is considered 100% bioavailable by definition because the compound is delivered directly into the bloodstream. Subcutaneous injection is different from intravenous administration, but it still bypasses the stomach and intestinal tract and can therefore provide substantially more predictable absorption for many peptides than swallowing them.
Oral administration presents several additional barriers. Peptides are chains of amino acids, and the digestive system contains enzymes specifically designed to break peptide bonds. Even if a peptide survives those enzymes, it must still cross the intestinal lining, which is generally a difficult barrier for relatively large, water-soluble peptide molecules.
This means two different things must happen for an orally administered peptide to achieve meaningful systemic exposure: the peptide needs to remain sufficiently intact through the gastrointestinal tract, and enough of that intact peptide then needs to cross the intestinal barrier. Surviving the stomach alone does not prove high oral bioavailability.
Why Injectable Peptides Usually Provide More Predictable Systemic Exposure
Subcutaneous injection places a peptide beneath the skin, where it can be absorbed without first passing through stomach acid, digestive enzymes and the intestinal barrier. This is one reason injectable delivery has historically been common for peptide and protein medications intended to act systemically.
Injection still does not guarantee that every molecule reaches circulation unchanged. Peptides can be metabolized at the injection site, in tissues and after entering circulation, and bioavailability differs considerably between individual compounds. However, injection removes several of the major variables involved in gastrointestinal delivery.
For a peptide whose intended effect requires systemic exposure, subcutaneous administration will therefore often be the more predictable route unless another delivery method has specifically been shown to work for that peptide. That conclusion concerns delivery, however, and should not automatically be converted into a claim that an injected form produces superior clinical outcomes when those outcomes have never been directly compared.
Why Oral Peptides Are More Difficult to Deliver
The main problems with oral peptides are enzymatic degradation and poor intestinal permeability. Digestive enzymes may fragment a peptide before it can be absorbed, while the intestinal lining prevents many larger hydrophilic molecules from crossing efficiently even when they remain intact.
This is why simply placing the same peptide used in an injectable formulation into a capsule does not necessarily create an equivalent oral product. Modern drug-development research uses absorption enhancers, protective formulations, nanoparticles, chemical modifications and other technologies specifically because natural oral absorption of many peptides is so poor.
A good example is semaglutide. Oral semaglutide uses the absorption enhancer SNAC to help the peptide cross the stomach lining, yet its absolute oral bioavailability remains very low compared with injection. It still works because enough semaglutide is absorbed to produce the required systemic exposure.
The useful lesson is not that oral peptides are ineffective. It is that oral effectiveness depends on the individual peptide, its potency and the formulation used to deliver it. A low percentage of absorption can sometimes be sufficient, while another peptide may require a completely different route.
Oral BPC-157 vs Injectable BPC-157
BPC-157 is one of the most interesting examples because oral and injectable administration are both widely discussed, yet the evidence is often oversimplified online.
BPC-157 has been described in the experimental literature as a stable gastric pentadecapeptide, with reported stability in human gastric juice. Animal studies have also reported biological effects when BPC-157 was delivered orally or directly into the gastrointestinal tract. These findings make oral BPC-157 scientifically more plausible than simply assuming that any swallowed peptide will immediately be destroyed.
However, gastric stability does not tell us the percentage that reaches the bloodstream. An intact BPC-157 molecule must still cross the intestinal barrier if systemic circulation is required, and reliable human pharmacokinetic studies directly comparing oral and subcutaneous BPC-157 are lacking.
From a delivery standpoint, subcutaneous BPC-157 bypasses those gastrointestinal barriers and would therefore be expected to provide more predictable systemic exposure. What cannot currently be concluded is that injectable BPC-157 has been proven clinically superior to oral BPC-157 in humans, because the necessary comparative human trials have not been performed.
Injectable BPC-157 is the more predictable route for systemic delivery, while oral BPC-157 has a stronger scientific rationale than many oral peptides because of its reported gastric stability and experimental oral activity. We simply do not have good human data showing how their actual systemic bioavailability or clinical effects compare.
Could Oral BPC-157 Have More Local Gastrointestinal Activity?
Another reason oral and injectable BPC-157 should not be judged solely by blood levels is that much of the experimental BPC-157 literature involves the gastrointestinal tract. Studies have investigated gastric and intestinal injury, ulceration and other gastrointestinal models, frequently using oral, intragastric or drinking-water administration.
If some of BPC-157’s activity occurs locally within gastrointestinal tissue, a peptide would not necessarily need extremely high systemic bioavailability to produce that local effect. This is similar to other drugs where the relevant question is not simply how much reaches the bloodstream, but whether enough reaches the intended tissue.
This does not prove that oral BPC-157 is superior for gastrointestinal purposes, nor does it establish an effective human treatment. It does explain why judging oral BPC-157 exclusively by expected systemic absorption may overlook part of the research surrounding the peptide.
Semax and Selank: Why Intranasal Delivery Is Different
Semax and Selank provide another useful example because intranasal administration has been part of their research history rather than simply being a convenient alternative created later.
The nasal mucosa has a substantial blood supply and allows certain compounds to be absorbed without first passing through the gastrointestinal tract. This avoids the digestive degradation that makes oral peptide delivery difficult. Nasal delivery is still imperfect because some material can be lost through mucociliary clearance, drainage or swallowing, and the actual amount absorbed depends heavily on the molecule and formulation.
Semax has been studied in humans using intranasal administration, and experimental research has also found different biological responses depending on whether Semax was administered intranasally or systemically. Selank likewise has a substantial research history involving intranasal use. For these compounds, nasal administration should therefore not be dismissed simply as an inferior substitute for injection.
The practical conclusion is that intranasal Semax and Selank have a legitimate route-specific research basis. That does not establish a universal percentage of nasal bioavailability or prove superiority over every other route, but there is considerably more justification for their nasal use than there would be for taking an arbitrary injectable peptide and converting it into a nasal spray.
What About Sublingual Peptides?
Sublingual administration attempts to deliver a compound through the mucosal tissue beneath the tongue. Because absorption can occur before the material reaches the stomach, this route may avoid some gastrointestinal degradation and first-pass metabolism.
Peptides still face substantial permeability problems across the oral mucosa, however. Molecular size, charge, formulation and the amount of time the product remains in contact with the tissue can all influence absorption. If much of a sublingual peptide is ultimately swallowed, that portion encounters the same gastrointestinal barriers as a conventional oral product.
For that reason, the word “sublingual” by itself is not evidence of high bioavailability. A meaningful claim about a sublingual peptide should ideally be supported by pharmacokinetic data for that specific peptide and formulation rather than assumptions based only on the delivery label.
GHK-Cu: Topical vs Systemic Delivery
GHK-Cu requires a somewhat different discussion because interest in the peptide extends beyond simply getting as much as possible into the bloodstream. GHK is a naturally occurring copper-binding tripeptide, and GHK-Cu has been investigated in relation to collagen synthesis, extracellular matrix remodeling, wound repair, angiogenesis and inflammatory processes.
Topical GHK-Cu has the better-developed human evidence base, particularly for skin-related applications. The objective of topical delivery is to expose skin tissue to the peptide rather than to maximize systemic blood concentrations. Skin is itself a substantial barrier, however, and GHK-Cu’s hydrophilic nature can limit penetration, which is why formulation and delivery technologies remain important.
Systemic or injectable GHK-Cu has a different rationale. By bypassing the skin barrier, systemic administration should produce broader distribution than applying the peptide to one localized area. Experimental and animal research provides biological support for systemic effects involving wound repair, collagen-related processes, angiogenesis and tissue remodeling, including reports of healing effects at locations distant from the site of administration.
That does not mean systemic GHK-Cu has been proven to increase whole-body collagen or provide superior anti-aging, connective-tissue or recovery benefits in humans. Current reviews continue to emphasize that evidence for injectable GHK-Cu outside established topical applications is largely preclinical and that quality human clinical data are lacking.
For someone specifically interested in broader collagen or regenerative effects, the reasoning behind systemic GHK-Cu is therefore understandable: systemic administration provides broader exposure and preclinical research suggests biological effects beyond the skin. But the evidence does not currently allow us to say that injecting GHK-Cu has been proven to improve systemic collagen production in humans.
The most accurate comparison is that topical GHK-Cu has stronger human evidence for localized skin applications, while systemic GHK-Cu has a plausible biological rationale and encouraging preclinical research for broader effects, but those broader human benefits remain unproven.
CJC-1295, Ipamorelin and GH Secretagogues
Growth hormone secretagogues are a particularly useful example of why peptides should not be grouped together too broadly.
CJC-1295 is a long-acting GHRH analogue that was investigated in human pharmacokinetic and pharmacodynamic studies using subcutaneous administration. Those studies demonstrated prolonged GH and IGF-1 responses, giving subcutaneous CJC-1295 an actual human research basis as a systemic delivery route.
Ipamorelin has also been investigated pharmacokinetically, including research showing that it can be absorbed through the nasal route. In one experimental pharmacokinetic study, intranasal ipamorelin achieved measurable systemic bioavailability. Other members of the growth hormone secretagogue family have also demonstrated activity after oral or intranasal administration, and non-peptide GH secretagogues have specifically been developed for oral use.
This means it would be incorrect to say that GH secretagogues as a group cannot work unless injected. The better question is whether a particular peptide in a particular formulation has evidence supporting that route.
For CJC-1295, subcutaneous administration has direct human research behind it, while robust human data establishing conventional oral CJC-1295 bioavailability are lacking. Ipamorelin has evidence showing that alternative delivery can be biologically possible, particularly intranasally, but this does not prove that commercially discussed oral, nasal or sublingual formulations are clinically equivalent to injection.
The practical answer is therefore more specific: injection remains the best-characterized route for CJC-1295 and a predictable systemic route for ipamorelin, but it is scientifically inaccurate to claim that these peptides or the broader GH-secretagogue class are inherently incapable of absorption through other routes.
Bioavailability and Effectiveness Are Not the Same Thing
One of the biggest sources of confusion in discussions about peptide administration is treating bioavailability and effectiveness as interchangeable terms.
Higher systemic bioavailability means that a greater proportion of the administered compound reaches systemic circulation. It does not automatically mean the product produces a better clinical result. Potency, receptor activity, half-life, tissue distribution and whether the intended effect is local or systemic all influence what ultimately happens.
This distinction explains why a topical peptide can make sense even if very little reaches systemic circulation, why an oral drug with low percentage bioavailability can still be effective, and why an injected peptide can produce much greater systemic exposure without necessarily having better clinical evidence.
The better question is not simply “Which route absorbs the most?” It is “Does this route deliver enough intact peptide to the tissue where it needs to act, and is there evidence that this actually produces the intended effect?”
Peptide Delivery Routes Compared
| Route | What It Generally Offers | Main Limitation | Useful Examples |
|---|---|---|---|
| Subcutaneous injection | Bypasses gastrointestinal barriers and generally provides predictable systemic exposure | Requires injection; absorption can still vary between peptides | CJC-1295, ipamorelin, BPC-157, systemic GHK-Cu |
| Oral | Convenient and needle-free | Enzymatic degradation and poor intestinal permeability | BPC-157 research; specially formulated oral semaglutide |
| Intranasal | Avoids the GI tract and allows absorption through nasal mucosa | Variable absorption, drainage and mucociliary clearance | Semax, Selank; experimental ipamorelin |
| Sublingual | Can potentially avoid some GI degradation | Peptide permeability through oral mucosa can remain low | Highly formulation-dependent |
| Topical | Direct local exposure when skin is the intended target | Skin itself strongly limits peptide penetration | GHK-Cu |
The table also shows why there is no universally superior peptide route. The route that produces the highest systemic exposure may be the logical choice for one peptide while being largely irrelevant to the intended use of another.
So Which Form Makes the Most Sense?
For BPC-157, subcutaneous administration provides the more direct and predictable route to systemic exposure, while oral administration has a legitimate scientific rationale because BPC-157 appears unusually stable in gastric conditions and has demonstrated oral activity in experimental models. Human research does not yet tell us exactly how their bioavailability or clinical outcomes compare.
For Semax and Selank, intranasal administration has a substantial research history and should be regarded as a legitimate delivery route rather than simply a weaker replacement for injection. For GHK-Cu, topical use has stronger human evidence for localized skin applications, while systemic use is supported mainly by biological rationale and preclinical research when broader collagen, repair or regenerative effects are the objective.
For CJC-1295, subcutaneous administration is the route characterized in human studies. Ipamorelin demonstrates that alternative routes can be possible, including measurable nasal absorption in experimental pharmacokinetic research, but that does not establish every oral, nasal or sublingual formulation as equivalent to injection.
And semaglutide demonstrates perhaps the clearest overall lesson: a peptide that naturally performs poorly when taken orally can still become a useful oral drug when a specifically engineered formulation allows enough of it to be absorbed.
The Bottom Line
Peptide bioavailability cannot be reduced to a rule that injections work while oral, nasal or topical peptides do not.
Injection generally offers the most predictable systemic delivery because it bypasses gastrointestinal degradation and intestinal absorption. That makes it especially useful when reliable circulating exposure is the objective. However, specific peptides can behave very differently depending on their stability, formulation and intended target.
BPC-157 appears unusually stable in gastric conditions, making oral activity more plausible than it would be for many peptides, although its actual human oral bioavailability compared with injection remains unknown. Semax and Selank have genuine intranasal research histories. GHK-Cu can be used locally through the skin or investigated systemically for broader biological effects, although systemic human evidence remains limited. CJC-1295 has been characterized primarily through subcutaneous human studies, while ipamorelin illustrates that at least some peptide GH secretagogues can achieve measurable absorption through alternative routes.
The clearest way to evaluate any peptide is therefore to ask three questions: Can this particular peptide survive the chosen route? Can enough intact peptide reach the intended tissue? And is there evidence that this route actually produces the desired biological or clinical effect?
Those questions provide a far more useful answer than assuming that one administration route is automatically superior for every peptide.
Disclaimer
This article is intended for educational purposes only and does not provide medical advice or instructions for using peptide products. Health Canada has warned that many injectable peptide products marketed online—including products labelled as BPC-157, CJC-1295, GHK-Cu and ipamorelin—are unauthorized drugs that have not been assessed by Health Canada for safety, efficacy or quality.